摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(3,5-dibromophenyl)-N-methylmethanamine | 216755-73-6

中文名称
——
中文别名
——
英文名称
1-(3,5-dibromophenyl)-N-methylmethanamine
英文别名
N-(3,5-dibromobenzyl)methylamine;3,5-dibromobenzyl-methylamine;[(3,5-Dibromophenyl)methyl](methyl)amine
1-(3,5-dibromophenyl)-N-methylmethanamine化学式
CAS
216755-73-6
化学式
C8H9Br2N
mdl
——
分子量
278.974
InChiKey
NLCATMNGDMWCBP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    293.6±25.0 °C(Predicted)
  • 密度:
    1.706±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    12
  • 氢给体数:
    1
  • 氢受体数:
    1

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Amine derivatives
    摘要:
    本发明涉及由公式(1)表示的胺衍生物或其盐。 R3代表C1-C3烷基,羟基化的C1-C5烷基,C1-C5酰基;C2-C5烯基,或一个卤素原子;k、l和m都是1到4的整数。) 这些化合物展现出优秀的抗真菌效果,因此作为抗真菌剂、抗真菌组合物、药物等非常有用。
    公开号:
    US06586633B1
  • 作为产物:
    描述:
    3,5-二溴苄基溴三乙胺 作用下, 以 盐酸甲醇N,N-二甲基甲酰胺甲胺 为溶剂, 以77.7%的产率得到1-(3,5-dibromophenyl)-N-methylmethanamine
    参考文献:
    名称:
    Amine derivatives
    摘要:
    本发明涉及由公式(1)表示的胺衍生物或其盐。 R3代表C1-C3烷基,羟基化的C1-C5烷基,C1-C5酰基;C2-C5烯基,或一个卤素原子;k、l和m都是1到4的整数。) 这些化合物展现出优秀的抗真菌效果,因此作为抗真菌剂、抗真菌组合物、药物等非常有用。
    公开号:
    US06586633B1
点击查看最新优质反应信息

文献信息

  • [EN] N-BENZYL-3-PHENYL-3-HETEROCYCLYL-PROPIONAMIDE COMPOUNDS AS TACHYKININ AND/ OR SEROTONIN REUPTAKE INHIBITORS<br/>[FR] COMPOSES DE N-BENZYL-3-PHENYL-3-HETEROCYCLYL-PROPIONAMIDE EN TANT QU'INHIBITEURS DE RECAPTAGE DE LA TACHYKININE ET/OU DE LA SEROTONINE
    申请人:GLAXO GROUP LTD
    公开号:WO2004005255A1
    公开(公告)日:2004-01-15
    The present invention relates to heterocyclic derivatives of formula (1) wherein R1 represents a 5 or 6 membered heteroaryl group, in which the 5-membered heteroaryl group contains at least one heteroatom selected from oxygen, sulphur or nitrogen and the 6-membered heteroaryl group contains from 1 to 3 nitrogen atoms, or R1 represents a 4,5 or 6 membered heterocyclic group, wherein saids 5 or 6 membered heteroaryl or the 4,5 or 6 membered heterocyclic group may optionally be substituted by one to three substituents, which may be the same or different, selected from (CH2)pR6, wherein p is zero or an integer from 1 to 4 and wherein R and R2- R6 are each as defined in the description and pharmaceutically acceptable salts and solvates thereof; process for their preparation and their use in the treatment of conditions mediated by tachykinins and/or by selective inhibition of serotonin reuptake transporter protein.
    本发明涉及式(1)的杂环衍生物,其中R1代表一个5或6成员杂芳基团,在其中5成员杂芳基团至少含有氧、硫或氮中选择的一个杂原子,而6成员杂芳基团含有1至3个氮原子,或者R1代表一个4、5或6成员杂环基团,其中所述的5或6成员杂芳基或4、5或6成员杂环基团可以选择地被1至3个取代基取代,所述取代基可以相同或不同,选择自(CH2)pR6,其中p为零或1至4的整数,其中R和R2-R6如描述中定义,并且其药学上可接受的盐和溶剂化合物;其制备方法及其在通过催产素介导的疾病和/或通过选择性抑制血清素再摄取转运蛋白的治疗中的用途。
  • Indanyl-piperazine compounds
    申请人:De Nanteuil Guillaume
    公开号:US20060223830A1
    公开(公告)日:2006-10-05
    A compound selected from those of formula (I): wherein: R 3 represents a hydrogen atom, and R 1 and R 2 together with the carbon atoms carrying them form a benzene, naphthalene or quinoline ring structure, each of the ring structures being optionally substituted, or R 1 represents a hydrogen atom, and R 2 and R 3 together with the carbon atoms carrying them form a benzene, naphthalene or quinoline ring structure, each of the ring structures being optionally substituted, n represents 1 or 2, —X— represents a group selected from —(CH 2 ) m —O-Ak-, —(CH 2 ) m —NR 4 -Ak-, —(CO)—NR 4 -Ak- and —(CH 2 ) m —NR 4 -(CO)—, m represents an integer between 1 and 6 inclusive, Ak represents an optionally substituted alkylene chain, and R 4 represents a hydrogen atom or an alkyl group, Ar represents an aryl or heteroaryl group, its enantiomers, diasteroisomers, and addition salts thereof with a pharmaceutically acceptable acid. Medical products containing the same which are useful in the treatment of conditions requiring a serotonin reuptake inhibitor and/or NK 1 antagonist.
    从公式(I)中选择的化合物:其中:R3代表氢原子,R1和R2与携带它们的碳原子一起形成苯、萘或喹啉环结构,每个环结构可选择地被取代,或R1代表氢原子,R2和R3与携带它们的碳原子一起形成苯、萘或喹啉环结构,每个环结构可选择地被取代,n代表1或2,-X-代表从-(CH2)m-O-Ak-、-(CH2)m-NR4-Ak-、-(CO)-NR4-Ak-和-(CH2)m-NR4-(CO)-中选择的基团,m代表1到6之间的整数,Ak代表可选择地取代的烷基链,R4代表氢原子或烷基基团,Ar代表芳基或杂环芳基基团,它的对映异构体、顺反异构体和与药用酸形成的加合物。含有这些化合物的医药产品在治疗需要血清素再摄取抑制剂和/或NK1拮抗剂的病症中有用。
  • 2-Substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors
    申请人:——
    公开号:US20040242592A1
    公开(公告)日:2004-12-02
    The present invention relates to piperazine derivatives of formula (I), wherein R represents halogen, C 1-4 alkyl, trifluoromethoxy or trifluoromethyl; R 1 is trifluoromethyl, C 1-4 alkyl, C 1-4 alkoxy, halogen or trifluoromethoxy; R 2 is hydrogen, C 1-4 alkyl or C 2-6 alkenyl; R 3 represents hydrogen or C 1-4 alkyl; n and m are independently 0 or an integer from 1 to 3; and pharmaceutically acceptable salts and solvates thereof, process for their preparation and their use in the treatment of condition mediated by tachykinins and/or by selective inhibition of the serotonin reuptake transporter protein. 1
    本发明涉及式(I)的哌嗪衍生物,其中R代表卤素、C1-4烷基、三氟甲氧基或三氟甲基;R1为三氟甲基、C1-4烷基、C1-4烷氧基、卤素或三氟甲氧基;R2为氢、C1-4烷基或C2-6烯基;R3代表氢或C1-4烷基;n和m分别独立地为0或1到3的整数;以及其药学上可接受的盐和溶剂合物,它们的制备方法以及它们在通过选择性抑制血清素再摄取转运蛋白和/或介导催吐肽的疾病治疗中的用途。
  • Chemical compounds
    申请人:Alvaro Giuseppe
    公开号:US20060128752A1
    公开(公告)日:2006-06-15
    The present invention relates to cyclic amine derivatives of formula(l) wherein R represents halogen, C 1-4 alkyl, cyano, C 1-4 alkoxy, trifluoromethyl or trifluoromethoxy; R 1 represents hydrogen, halogen, C 3-7 cycloalkyl, hydroxy, nitro, cyano or C 1-4 alkyl optionally substituted by halogen, cyano or C 1-4 alkoxy; R 2 represents hydrogen or C 1-4 alkyl; R 3 and R 4 independently represent hydrogen, cyano, C 1-4 alkyl or R 3 together with R 4 represents C 3-7 cycloalkyl; R 5 represents trifluoromethyl, S(O) t C 1-4 alkyl, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethoxy, halogen or cyano; R 6 represents hydrogen or (CH 2 )rR 7 ; R 7 represents hydrogen, C 3 7 cycloalkyl, NH(C 1-4 alkylOC 1-4 alkoxy), NH(C 1-4 alkyl), N(C 1-4 alkyl) 2 , OC(O)NR 9 R 8 , NR 8 C(O)R 9 or C(O)NR 9 R 8 ; R 9 and R 8 independently represent hydrogen, C 1-4 alkyl or C 3-7 cycloalkyl; m represents zero or an integer from 1 to 4; n represents 1 or 2; p is zero or an integer from 1 to 3; q is an integer from 1 to 3; r is an integer from 1 to 4; t is 0, 1 or 2; provided that when m is 0, p is 2, q , r and n represent 1, R 1 , R 2 ,R 3 , R 4 , R 5 and R 7 are hydrogen and R is chlorine, R 5 is not iodine; and pharmaceutically acceptable salts and solvates thereof; process for their preparation and their use in the treatment of conditions mediated by tackykinins and/or by selective inhibition of serotonin reuptake transporter protein.
    本发明涉及式(I)的环状胺衍生物,其中R代表卤素、C1-4烷基、氰基、C1-4烷氧基、三氟甲基或三氟甲氧基;R1代表氢、卤素、C3-7环烷基、羟基、硝基、氰基或C1-4烷基,可选地被卤素、氰基或C1-4烷氧基取代;R2代表氢或C1-4烷基;R3和R4独立地代表氢、氰基、C1-4烷基或R3和R4一起代表C3-7环烷基;R5代表三氟甲基、S(O)tC1-4烷基、C1-4烷基、C1-4烷氧基、三氟甲氧基、卤素或氰基;R6代表氢或(CH2)rR7;R7代表氢、C37环烷基、NH(C1-4烷基OC1-4烷氧基)、NH(C1-4烷基)、N(C1-4烷基)2、OC(O)NR9R8、NR8C(O)R9或C(O)NR9R8;R9和R8独立地代表氢、C1-4烷基或C3-7环烷基;m代表零或1至4的整数;n代表1或2;p为零或1至3的整数;q为1至3的整数;r为1至4的整数;t为0、1或2;但当m为0,p为2,q、r和n均为1,R1、R2、R3、R4、R5和R7均为氢,R为氯时,R5不为碘;以及其药学上可接受的盐和溶剂化合物;其制备方法和在治疗由粘附素介导和/或选择性抑制血清素再摄取转运蛋白介导的疾病中的应用。
  • N-benzyl-3-phenyl-3-heterocyclyl-propionamide compounds as tachykinin and/or serotonin reuptake inhibitors
    申请人:Alvaro Giuseppe
    公开号:US20060058348A1
    公开(公告)日:2006-03-16
    The present invention relates to heterocyclic derivatives of formula (I) wherein R represents halogen, C 1-4 alkyl, cyano, C 1-4 alkoxy, trifluoromethyl or trifluoromethoxy; R 1 represents a 5 or 6 membered heteroaryl group, in which the 5-membered heteroaryl group contains at least one heteroatom selected from oxygen, sulphur or nitrogen and the 6-membered heteroaryl group contains from 1 to 3 nitrogen atoms, or R 1 represents a 4, 5 or 6 membered heterocyclic group, wherein saids 5 or 6 membered heteroaryl or the 4, 5 or 6 membered heterocyclic group may optionally be substituted by one to three substituents, which may be the same or different, selected from (CH 2 ) p R 6 , wherein p is zero or an integer from 1 to 4 and R 6 is selected from: halogen, C 1-4 alkoxy, C 1-4 alkyl, C 3-7 cycloalkyl, C 1-4 alkyl optionally substituted by halogen, cyano or C 1-4 alkoxy, hydroxy, cyano, nitro, trifluoromethyl, carboxy, NH(C 1-4 alkyl), N(C 1-4 alkyl) 2 NH(C 3-7 cycloalkyl), N(C 1-4 alkyl)(C 3-7 cycloalkyl); NH(C 1-4 alkylOC 1-4 alkoxy), OC(O)NR 7 R 8 , NR 8 C(O)R 7 or C(O)NR 7 R 8 ; R 2 represents hydrogen, or C 1-4 alkyl; R 3 and R 4 independently represent hydrogen, C 1-4 alkyl or R 3 together with R 4 represents C 3-7 cycloalkyl; R 5 represents trifluoromethyl, S(O) q C 1-4 alkyl, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethoxy, halogen or cyano; R 7 and R 8 independently represent hydrogen, C 1-4 alkyl or C 3-7 cycloalkyl; L is a single or a double bond; n is an integer from 1 to 3; m is zero or an integer from 1 to 3; q is zero or an integer from 1 to 2; provided that a) when L is a double bond, R 1 is not an optionally substituted 5 or 6 membered heteroaryl group, in which the 5-membered heteroaryl group contains at least one heteroatom selected from oxygen, sulphur or nitrogen and the 6-membered heteroaryl group contains from 1 to 3 nitrogen atoms; b) the group R 1 is linked to the carbon atom shown as * via a carbon atom; and c) when the heteroatom contained in the group R 1 is substituted, p is not zero; and pharmaceutically acceptable salts and solvates thereof; process for their preparation and their use in the treatment of conditions mediated by tachykinins and/or by selective inhibition of serotonin reuptake transporter protein.
    本发明涉及公式(I)的杂环衍生物,其中R代表卤素、C1-4烷基、氰基、C1-4烷氧基、三氟甲基或三氟甲氧基;R1代表一个5或6成员的杂芳基团,其中5成员杂芳基团含有至少一个从氧、硫或氮中选择的杂原子,6成员杂芳基团含有从1到3个氮原子,或R1代表一个4、5或6成员的杂环基团,其中所述的5或6成员杂芳基或4、5或6成员的杂环基团可以选修为1至3个取代基,所述取代基可以是相同的或不同的,选自(CH2)pR6,其中p为零或1至4的整数,R6选自:卤素、C1-4烷氧基、C1-4烷基、C3-7环烷基、C1-4烷基(可选地取代为卤素、氰基或C1-4烷氧基)、羟基、氰基、硝基、三氟甲基、羧基、NH(C1-4烷基)、N(C1-4烷基)2NH(C3-7环烷基)、N(C1-4烷基)(C3-7环烷基);NH(C1-4烷基OC1-4烷氧基)、OC(O)NR7R8、NR8C(O)R7或C(O)NR7R8;R2代表氢或C1-4烷基;R3和R4独立地代表氢、C1-4烷基或R3与R4一起代表C3-7环烷基;R5代表三氟甲基、S(O)qC1-4烷基、C1-4烷基、C1-4烷氧基、三氟甲氧基、卤素或氰基;R7和R8独立地代表氢、C1-4烷基或C3-7环烷基;L是单键或双键;n是1至3的整数;m是零或1至3的整数;q是零或1至2的整数;前提是a)当L是双键时,R1不是可选修饰的含有至少一个从氧、硫或氮中选择的杂原子的5或6成员杂芳基团,6成员杂芳基团含有从1到3个氮原子;b)R1团与所示碳原子通过碳原子相连;c)当R1团中含有的杂原子被取代时,p不为零;以及其药学上可接受的盐和溶剂酸化物;它们的制备过程及其在治疗由Tachykinins介导和/或通过选择性抑制血清素再摄取转运蛋白介导的疾病中的用途。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐